331 related articles for article (PubMed ID: 23308186)
1. Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
Cadavid D; Jurgensen S; Lee S
PLoS One; 2013; 8(1):e53297. PubMed ID: 23308186
[TBL] [Abstract][Full Text] [Related]
2. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
[TBL] [Abstract][Full Text] [Related]
3. Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.
Voloshyna N; Havrdová E; Hutchinson M; Nehrych T; You X; Belachew S; Hotermans C; Paes D
Eur J Neurol; 2015 Mar; 22(3):570-7. PubMed ID: 25511792
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis.
McCormack PL; Scott LJ
BioDrugs; 2004; 18(5):343-7. PubMed ID: 15377176
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data.
Cree BA; Stuart WH; Tornatore CS; Jeffery DR; Pace AL; Cha CH
Arch Neurol; 2011 Apr; 68(4):464-8. PubMed ID: 21482925
[TBL] [Abstract][Full Text] [Related]
6. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.
McCormack PL; Scott LJ
CNS Drugs; 2004; 18(8):521-46. PubMed ID: 15182221
[TBL] [Abstract][Full Text] [Related]
7. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.
Weinstock-Guttman B; Galetta SL; Giovannoni G; Havrdova E; Hutchinson M; Kappos L; O'Connor PW; Phillips JT; Polman C; Stuart WH; Lynn F; Hotermans C
J Neurol; 2012 May; 259(5):898-905. PubMed ID: 22008873
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
Hutchinson M; Kappos L; Calabresi PA; Confavreux C; Giovannoni G; Galetta SL; Havrdova E; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
J Neurol; 2009 Mar; 256(3):405-15. PubMed ID: 19308305
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
Walter E; Berger T; Bajer-Kornek B; Deisenhammer F
J Med Econ; 2019 Mar; 22(3):226-237. PubMed ID: 30522373
[TBL] [Abstract][Full Text] [Related]
10. Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making.
van Munster CEP; Kaya L; Lam KH; Kalkers NF; Killestein J; Uitdehaag BMJ
Mult Scler Relat Disord; 2020 Feb; 38():101489. PubMed ID: 31731213
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis.
Belachew S; Phan-Ba R; Bartholomé E; Delvaux V; Hansen I; Calay P; Hafsi KE; Moonen G; Tshibanda L; Vokaer M
Eur J Neurol; 2011 Feb; 18(2):240-245. PubMed ID: 20561044
[TBL] [Abstract][Full Text] [Related]
12. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
[TBL] [Abstract][Full Text] [Related]
14. Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
Freedman MS; Brod S; Singer BA; Cohen BA; Hayward B; Dangond F; Coyle PK
J Neurol; 2020 Jan; 267(1):64-75. PubMed ID: 31559532
[TBL] [Abstract][Full Text] [Related]
15. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.
Cohen JA; Cutter GR; Fischer JS; Goodman AD; Heidenreich FR; Kooijmans MF; Sandrock AW; Rudick RA; Simon JH; Simonian NA; Tsao EC; Whitaker JN;
Neurology; 2002 Sep; 59(5):679-87. PubMed ID: 12221157
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies.
Hernandez L; O'Donnell M; Postma M;
Pharmacoeconomics; 2021 Feb; 39(2):243-256. PubMed ID: 32989685
[TBL] [Abstract][Full Text] [Related]
17. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.
Vollmer TL; Phillips JT; Goodman AD; Agius MA; Libonati MA; Giacchino JL; Grundy JS
Mult Scler; 2004 Oct; 10(5):511-20. PubMed ID: 15471366
[TBL] [Abstract][Full Text] [Related]
18. Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis.
Koch MW; Mostert J; Repovic P; Bowen JD; Uitdehaag B; Cutter G
Neurology; 2021 Jan; 96(1):e111-e120. PubMed ID: 33106389
[TBL] [Abstract][Full Text] [Related]
19. The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis.
Cohen JA; Krishnan AV; Goodman AD; Potts J; Wang P; Havrdova E; Polman C; Rudick RA
JAMA Neurol; 2014 Nov; 71(11):1386-93. PubMed ID: 25178496
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics of responders to interferon therapy for relapsing MS.
Waubant E; Vukusic S; Gignoux L; Dubief FD; Achiti I; Blanc S; Renoux C; Confavreux C
Neurology; 2003 Jul; 61(2):184-9. PubMed ID: 12874396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
